|ω-conotoxins GVIA, MVIIA and CVID: SAR and clinical potential|
Schroeder, C.I.; Lewis, R.J. (2006). ω-conotoxins GVIA, MVIIA and CVID: SAR and clinical potential. Mar. Drugs 4(3): 193-214
In: Marine Drugs. Molecular Diversity Preservation International (MDPI): Basel. ISSN 1660-3397, more
|Authors|| || Top |
- Schroeder, C.I.
- Lewis, R.J.
Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain.